Please try another search
For the fiscal year ended 31 December 2021, Lepu Biopharma Co Ltd revenues was not reported. Net loss increased 74% to RMB1.01B. Higher net loss reflects Research and development expenses increase from RMB354.4M to RMB791.2M (expense), Administrative expenses increase of 67% to RMB156.2M (expense), Equity Earnings Net of Income Tax increase of 46% to RMB17.7M (expense).
Period Ending: | Jun 30, 2022 | Mar 31, 2022 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Revenue | ||||
Gross Profit | ||||
Operating Income | -155.34 | -155.34 | -245.6 | -245.6 |
Net Income | -172.14 | -172.14 | -255.98 | -255.98 |
Period Ending: | Jun 30, 2022 | Mar 31, 2022 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Total Assets | 2642.96 | 2642.96 | ||
Total Liabilities | 1430.71 | 1430.71 | ||
Total Equity | 1212.25 | 1212.25 |
Period Ending: | Jun 30, 2022 | Mar 31, 2022 | Jun 30, 2021 | Mar 31, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -96.39 | -96.39 | -177.15 | -177.15 |
Cash From Investing Activities | -5.41 | -5.41 | 25.27 | 25.27 |
Cash From Financing Activities | 413.91 | 413.91 | 121.64 | 121.64 |
Net Change in Cash | 329.66 | 329.66 | -30.82 | -30.82 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review